Product Description
AC0676 is an investigational orally bioavailable, chimeric degrader of Bruton's Tyrosine Kinase (BTK) for the potential treatment of relapsed/refractory B-cell malignancies. In preclinical studies, AC0676 has demonstrated potent and selective BTK protein degradation with broad coverage of BTK wildtype and mutants (including C481S, L528W, and others), favorable pharmacological properties, as well as promising anti-tumor activities in animal models. (Sourced from: https://www.accutarbio.com/accutar-biotechnology-announces-fda-clearance-of-ind-application-for-phase-1-trial-of-ac0676-in-b-cell-malignancies/)
Mechanisms of Action: Btk Degrader
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Accutar Biotechnology
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: B-Cell Marginal Zone Lymphoma|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05780034 |
AC676-001 | P1 |
Recruiting |
Follicular Lymphoma|Waldenstrom Macroglobulinemia|Diffuse Large B-Cell Lymphoma|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|B-Cell Marginal Zone Lymphoma |
2026-03-31 |
50% |
2025-10-03 |
Primary Endpoints |